{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:29:53Z","timestamp":1785886193373,"version":"3.56.0"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Interleukin 5 is an important target for the treatment of eosinophil\u2010associated diseases including eosinophilic asthma. SHR\u20101703 is an innovative humanized anti\u2010interleukin\u20105 monoclonal antibody designed to improve asthma control. This study aimed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR\u20101703 in asthma patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the single ascending dose study, eligible patients were randomized to receive SHR\u20101703 (400 or 600\u2009mg) or placebo and followed up to Day 281. Primary endpoints were safety and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most treatment\u2010emergent adverse events (TEAEs) were mild or moderate. The incidence of TEAEs was comparable between the SHR\u20101703 and placebo groups. The median (range) T\n                      <jats:sub>max<\/jats:sub>\n                      was 13.9 (7.0\u201314.1) and 10.3 (10.0\u201314.0) days for SHR\u20101703 400 and 600\u2009mg, respectively. SHR\u20101703 at 400 and 600\u2009mg has an extended mean (standard deviation) half\u2010life of 75.1 (11.1) and 72.6 (12.7) days. Meanwhile, SHR\u20101703 markedly and rapidly reduced peripheral blood eosinophils by over 50% in 1\u2009day. The largest mean (standard deviation) decline of eosinophils from baseline reached 87.7 (5.8)% for 400\u2009mg and 91.1 (4.7)% for 600\u2009mg, with the effect sustained over 100\u2009days. The eosinophil levels remained below the baseline up to the end of follow\u2010up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SHR\u20101703 was well\u2010tolerated and showed promising efficacy in eosinophilic asthma patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70439","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T09:50:19Z","timestamp":1767693019000},"page":"1673-1684","source":"Crossref","is-referenced-by-count":1,"title":["SHR\u20101703, a novel long\u2010acting anti\u2010interleukin\u20105 monoclonal antibody, in asthma patients: A randomized, double\u2010blind, placebo\u2010controlled phase 1 study"],"prefix":"10.1002","volume":"92","author":[{"given":"Ling","family":"Yang","sequence":"first","affiliation":[{"name":"Clinical Trial Center West China Hospital of Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiu","family":"He","sequence":"additional","affiliation":[{"name":"Clinical Trial Center West China Hospital of Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1687-9816","authenticated-orcid":false,"given":"Meng","family":"Fu","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Li","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1030-2320","authenticated-orcid":false,"given":"Zhu","family":"Luo","sequence":"additional","affiliation":[{"name":"Clinical Trial Center West China Hospital of Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)33311\u20101"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2015.36.3908"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105875"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01514"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050384"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637948"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.4103\/0970\u20102113.63609"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221113"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.013"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxp102"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315609251"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1710\u20101492\u20109\u201030"},{"key":"e_1_2_13_14_1","unstructured":"Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma2023."},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2361065"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.726"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/11584340\u2010000000000\u201000000"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.205"},{"issue":"9","key":"e_1_2_13_19_1","first-page":"564","article-title":"Reslizumab (Cinqair): an Interleukin\u20105 antagonist for severe asthma of the eosinophilic phenotype","volume":"42","author":"Hom S","year":"2017","journal-title":"Pharm Ther"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S392155"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.642359"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15002"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359\u20106446(05)03638\u2010X"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C300470200"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03496-6"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206\u2010525OC"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70439","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:48:00Z","timestamp":1779781680000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/bcp.70439"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70439","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]}}}